Starving the Cancer and Feeding the Body

Taking the blood type into account, a cancer diet is specifically formulated to provide nutrition to the body and its functions while denying nutrition to the tumor. Patients with tumoral activities are in a state of cachexia (i.e., their bodies degenerate and lose protein and organ mass while the cancer grows). What is cachexia? It is a process of cellular destruction. which occurs because tumor cells are stealing nutrients from the body. We know that tumor cells grow in dextrorotation, meaning that the DNA rotates to the right as the cells reproduce. Subsequently, we starve the tumor while nourishing the healthy cells with nutrients and medications that rotate to the left. Some examples are levulose acids switched to the left side, lipids with a negative polarization, and glucose that rotates to the left. All these substances nourish the body, not the tumor. Cancer patients need more nutrients, proteins, carbohydrates, lipids minerals, vitamins, and enzymes in their diets than do noncancer patients because cancer cells take and monopolize all the nutrients from their bodies. The cancer cells grow through the process of fermentation. They don’t need oxygen to survive, and they milk all the glucose and proteins from the body and produce lactic acid. Cancer cells can starve a body for months. Cancer cells switch the pH (acid/alkali balance) in the patient’s system and create a positively charged environment in which to grow. Cancer cells have cycles: the pH in the body, normally alkaline, changes to acidic when cancer cells need to nourish themselves to grow. The body’s internal environment is changed and the cancers growth aided. At the same time, the body’s immune system is prevented from functioning because a protective gel is formed around the tumor cells. Cancer cells create specific receptors to attract nutrients and specific carriers to grow and spread within the acidic pH. They connect and attach themselves to normal cells and rob them of their nutrients. Cancer cells also switch electrical impulses within the bloodstream. Cancer cells are positively charged. and red blood cells are negative. Once the cancer cells steal all the nutrients from negatively charged, noncancerous cells, they slough them off and attract more red blood cells. BREAKING THE CANCER CODE – 74 In the normal body, the pH cycle from 10:00 a.m. to 3:00 p.m. is usually acidic, and from 3:00 to 10:00 p.m., it is alkaline. Then it switches back sometime in between. Cancer therapy must be given when the patient is in the acid phase. Any therapy we give during this specific time will attack the tumor while it is attempting to grow. Nontoxic medications and nourishment for the noncancerous cells are given from 3:00 to 10:00 p.m. while the cancer cells are less active. Cancer patients especially need to get all their nutrients from the best sources that do not contain any chemicals or preservative. The goal of using diet as a cancer therapy is to diminish the levels of harmful chemicals and carcinogenic agents that could adversely affect the DNA of the healthy cells, to give support to the cells to get well, and for the immune system to function normally.

How to Use Your Diet to Heal

Once a person has been diagnosed with cancer, the idea of eating healthy is no longer an option. In order for their body (a.k.a. life vehicle) to function and heal, the fuel now has to be premium, and the maintenance of the vehicle is daily. Never has diet been more important than when healing a condition like cancer. The foods and drinks we ingest give us energy and the tools we need for our cells to function efficiently and harmoniously. In today’s standard American diet (SAD) with heavily processed foods, the very substances designed to nourish us can cause our organs to malfunction and make us sick. For many years, food was ignored as a cancer-causing agent. Doctors know today that certain foods can be initiators for cancer and other illnesses. Our bodies are harmed by foods containing preservatives, antibiotics, and pesticides, to name a few. The many forms of sugar-from modified high-fructose corn syrup to pure cane syrup to brown rice syrup to agave nectar-all make foods tastier as they stimulate appetite and cancer cells. Because the standard American lifestyle is rush-rush-rush with little time to relax, many of us eat and chew our foods improperly, which means we absorb less of the nutrients available in what we consume. Cancer healing is a wake-up call to make changes in many of these areas.

cancer-diet

Healing Cancer with Diet

cancer-diet

Some of the dietary plans used to treat illness and cancer have been vegetarian, macrobiotic, alkaline, and fasting diets. We suggest that the best way to choose a diet is to know the patient’s genes and body. This will help the doctor to prescribe a revised and improved approach to a proper diet specific for the patient. The type of diet chosen is an important factor in fighting cancer because the type of nutrition the body receives can slow down or stop the growth of cancer cells. All metabolic reactions in the cells depend on the certain nutrient’s presence and water. By using the blood technique of matching patients’ types with diet, we help stop cancer cells from growing and transform them to normal cells. At many health centers and cancer centers, including ours, we use diets that are determined by blood type and don’t put additional stress on the patient’s body. Cancer patients are already under tremendous stress, and their diets should create harmony and not add challenges to their bodies. We have seen tremendous benefits and positive results by incorporating more plant-based, nutrient-dense, and whole-food-specialized diets into their treatment plans and lifestyles. There is a huge movement in the United States toward these healthier preservative-and sugar-free diets that open up a whole new lifestyle. One of the best companies leading the way is Whole Foods Market. The standard American diet has been omnivorous (i.e., we consume both animal and vegetable products). We actually do need to eat a wide variety of foods that contain proteins, carbohydrates, and lipids to keep our bodies functioning well. That is the purpose of nutrition! We also know that the fast-food society has taken a toll on most of us. Now, when patients need to heal, a dietary regimen for cancer patients should take into account the genetic constitution of the patient.

Magnetic nanoparticles to cure Cancer

Immunotherapy against cancer translates as the activation of the immune system in the body to attack tumor cells, this type of treatments has gained much importance in recent decades as a viable strategy for the treatment of cancer. Immunotherapeutic treatments recently approved by the FDA have generated remission in patients with previously bleak results and have expanded the number of tools available to treat cancer. The nanoparticles, in different ways, whether polymeric, liposomal and metallic, naturally turn to highly irrigated tissues such as the spleen and lymphatic organs, which makes them good candidates for the administration of immunotherapeutic agents. Metal nanoparticle formulations, in particular, are useful because of their potential to enhance their ability to generate optical or laser-based therapeutic methods with magnetic fields.

When the particles are administered intravenously, the iron particle within a magnetic field, turns from one side to another, generating a constant heat. What produces a metabolic change in the cancer cell and generates its destruction in such a way that if it is possible to administer them directly in the tumor it is literally possible to generate the elimination of the tumor cells by means of heat.

Tumors need to grow rapidly and to achieve this, they stimulate the production of internal blood vessels. One of the side effects of this excessive stimulation in neovascularization is that the vessels are friable and lack effective lymphatic drainage, which helps the nanoparticles reach the parenchyma of the tumor.

Despite the important preclinical reports demonstrated by many research groups in the last twenty years, only a few metal nanoparticles have successfully entered clinical trials.

In our hospital we are working with NanoDynamics Inc. They as providers are one of the companies in the USA. They have FDA approval. Within the protocol registered in the national health institutes, there are several inclusion criteria among which candidate patients are selected to receive immunotherapy treatment.

• First, the patient must be between 25 and 75 years old

• The patient must have a neoplastic disease with solid tumor

• A progression prior to chemotherapy is important

• Two local doses should be administered if possible or 3 systemic doses

• The stimulation with the magnetic fields must be done twice a day

The protocol is carried out within the clinic and it is important to administer an important dose of antioxidant agents daily, the reason is to be able to cushion the components produced by the cell death of the tumor cells. Also control the food due to the amount of toxic components and pesticides contained in some types of food that can interfere with the distribution of magnetic particles.

Immune evasion is a characteristic of all types of cancer and contributes to tumor growth. In clinically healthy people, the body’s immune system recognizes abnormal cells and facilitates their destruction. Tumor cells evade such destruction by eliminating tumor antigens and immunosuppressing the attack function of T cells.

Cancer vaccines can induce the production and stimulation of T cells by being stimulated with tumor antigens, which often reside in the spleen, skin or lymphatic tissues. By promoting the production of dendritic cells, they interact with the CD8 + and Natural Killers T cells, initiating the maturation, expansion and migration processes to attack the sites of neoplasms.

If, together with immunostimulant therapy, nanoparticle therapy is administered, it is possible that a potentiation of the immune response is generated with the heat generated thereby generating the regression of the tumor masses.

Bibliography

  • D. Hanahan, R.A. Weinberg, Cell 144 (2011) 646–674.
  • R. Kim, M. Emi, K. Tanabe, Immunology 121 (2007) 1–14.
  • A.B. Frey, Vaccine 33 (2015) 7393–7400.
  • S. Farkona, E.P. Diamandis, I.M. Blasutig, BMC Med. 14 (2016) 73.
  • J.J. Moon, B. Huang, D.J. Irvine, Adv. Mater. 24 (2012) 37
  • B. Yu et al., Int. J. Nanomed. 12 (2017) 2553–2567.
  • R. Mejias et al., Biomaterials 32 (2011) 2938–2952.
  • S.K. Libutti et al., Clin. Cancer Res. 16 (2010) 6139–6149.
  • M.M. Shenoi et al., Mol. Pharm. 10 (2013) 1683–1694.
  • C. Ge et al., Chin. Clin. Oncol. 6 (2017) 18.
  • M. Scholz, S. Yep, et al., Immunotargets Ther. 6 (2017) 11–16.
  • Q. Zhou et al., ACS Nano 10 (2016) 2678–2692.

CRISPR Protocol: Inhibition of mTOR by means of CRISPR / Cas9 as an alternative to regulate the proliferation of cancer cells.

Background:

Proliferation is an important part of cancer development and progression. This is manifested by the expression and / or altered activity of proteins related to the cell cycle. The constitutive activation of many signal transduction pathways also stimulates cell growth. Once tumors appear, growth and metastasis can be supported by the overproduction of appropriate hormones (in hormone-dependent cancers), by promoting angiogenesis, by the transition from epithelium to mesenchymal, by triggering autophagy and by take the signals of the surrounding stromal cells. Cancer therapy, which involves cytotoxic drugs, destroys cells that have a high basal level of proliferation and regeneration. While this type of therapy targets tumor cells, it affects non-tumor cells that proliferate rapidly. The objective of this study is to program through CRISPR-Cas9 a sequence to genetically inhibit the proliferation pathway of the rapamycin Diana protein in mammalian cells (mTOR) to alter and block the proliferation of tumor cells by coupling it to the target cells by electroporation medium.

The mTOR protein is involved in the control of the initiation of RNA transcription, organization of the actin cell cytoskeleton, membrane traffic, ribosome formation and growth regulation, cell proliferation.

The two proteins that interact with mTOR, raptor and rictor, define the different arms of the mTOR path. The raptor-mTOR pathway regulates cell growth (accumulation of cell mass) through S6K1 and 4E-BP1. It responds to nutrients and growth factors, partly due to regulators such as TSC1 / TSC2 and rheb. The rictor-mTOR complex regulates Akt / PKB, PKCα, Rho / rac, to control cell survival, proliferation, metabolism and cytoskeleton. The binding of growth factors to receptors on the active PI3K cell surface, to generate PIP3, which recruits the PKD1 and Akt / PKB kinase to the membrane. Akt / PKB is activated by phosphorylation in two different places. The rictor-mTOR complex phosphorylates Akt / PKB in serine 473, in a hydrophobic motif, which facilitates phosphorylation by PKD1 in the Akt / PKB activation loop in threonine 308.

Neoplastic cells require a large cocktail of cytokines for cell cycle control, proliferation and metastasis. Inhibitors directed against the metabolic pathways generated by these cytokines are generating promising results in the treatment of solid tumors and leukemia. As mentioned earlier, the mTOR protein seems to be an essential protein that is in the PI3K signaling pathway. On the other hand, there is solid experimental evidence that reinforces the role of mTOR as a key regulator of the cell cycle, directing expansion, growth and proliferation.

Goals:

Generate a vaccine using CRISPR Cas9 to couple an interference sequence to P42345 that represents the mTOR genetic code.

Methodology:

An interference sequence will be designed for the initiators and part of the mTOR coding sequence in order to couple it to the CRISPR-Cas9 system and generate a selective genetic inhibitor of cell proliferation.

To evaluate the effectiveness of the designed system,

http://www.biocancer.com/journal/194/la-ruta-mtor-como-diana-terapeutica

http://www.rcsb.org/pdb/protein/P42345

Use of Oncolytic Viruses and Immunostimulation Therapy

For several years now, HSV-1 has been used in the biotechnology industry as a vector for transfection of eukaryotic cells and has also been used in different clinical trials. In 2007, researchers from London reported that they treated successfully (although modestly) a rare form of blindness caused by a mutation in a single gene (the gene encodes a protein that is important for producing pigments that absorb light in the eye). Most importantly, the patient did not suffer any side effects. More recently, researchers in France used a modified HSV-1 to introduce genes to correct a rare brain disorder (adrenoleukodystrophy) in two children.

Oncolytic viruses (VO) use cancer cells to replicate and selectively destroy altered tissue spreading within the tumor, without damaging normal tissue. In addition to this direct oncolytic activity, VOs are also very effective in inducing immune responses in infected tumor cells.

The VOs encompass a wide variety of DNA and RNA viruses that are selective for cancer or can be genetically modified. The VOs provide a diverse platform for immunotherapy; they act as vaccines in situ and can be armed with immune modulating transgenes or combined with other immunotherapies such as administration of Dendritic cells and Tumor Infiltrating Lymphocytes (TIL-NK)

Many of the characteristics of the neoplastic tissue provide a permissive environment for oncolytic viruses.

OVs have many features as an advantage in different therapeutic uses:

1.- Cancer cells cannot develop resistance to Oncolytic Viruses

2.- They replicate selectively in tumor cells are not pathogenic.

3.- There is a possibility that the dose of virus in the tumor increases over time.

4.- Safety features can be incorporated, such as drug sensitivity and immunity or Viral Neutralization mechanisms.

An important issue for therapy with Oncolytic Viruses is either systemic or local administration. With intravenous systemic administration multiple tumors can be attacked, however, intratumoral administration is more effective and the number of virions in the tumor tissue is increased in less time.

There have been numerous clinical trials of VO for cancer. As expected, most have been in phase I with some phase II trials. There is currently a phase III trial of an oncolytic HSV1 for melanoma (talimogene laherparepvec, T-Vec) of this Visur strain there is the final analysis showing results that will lead to the first approval by the US FDA. UU. From a VO for tumors.

Like many cancer vaccination strategies, our collaboration with the team of researchers from the National Institutes of Health has developed a type of OV that apart from generating lysis of cancer cells leaves an antigen in the survivors (for patenting ATC ) that can induce selective adaptive immune response in the body’s defense cells. The combination of the expression of ATC Known Tumor Antigens in the tumor and OV-mediated cell death induces enhanced migration and activation of T cells compared to infected tumor cells that only express viral antigens. This is coupled to a main vaccine strategy (which contains a VSH-1 blocking agent which limits the replication of the virus used.

The presence of HSV-1 has been detected worldwide. It is acquired mostly during childhood and lasts a lifetime. The vast majority of HSV-1 infections are cold sores (infections in the mouth or around them, so it is sometimes called cold sores, labial) without any vital commitment.

The viruses and their code were initially developed in plasmids to transfect bacterial cells and produce as many viruses as possible, subsequently tested with renal adenocarcinoma cell lines (769-p), squamous cell carcinoma (UPCI: SCC152) and corroborated that the virus replicated and generated lysis of cells cultured in vitro, we are currently carrying out tests with hepatocarcinoma and small cell lung carcinoma cell lines, to demonstrate their oncolytic activity.

Finally, we will evaluate the oncolytic activity in a murine model to be able to translate the technology to a phase 1 clinical study in humans, with this background our work group is in the task of innovating and developing new tools aimed at the well-being of our patients and the population with genetic predisposition to solid neoplasms.